Abstract 193P
Background
Humanized immune system mice provide a useful platform for various immune research fields. However, there have been limitations such as insufficient engraftment of human cells and development of graft-versus-host disease (GVHD). To overcome the limitations, we generated a novel immunodeficient mouse strain, CD47; Prkdc; IL2rg triple KO (STKO) mice based on SID mice (Prkdc; IL2rg double KO). Because CD47 plays an important role in engraftment of human tissues and cells, we expected improved human cell engraftment and GvHD development in STKO mice.
Methods
4-week female SID and STKO mice were applied to generate HSC hu-mice. 1X105 hCD34+ HSCs were injected within 24 hours of myeloablation applying busulfan. For generating PBMC hu-mice 5X106 PBMCs were injected. To overcome lethal GvHD, low dose PBMCs were applied to 4 weeks old mice. The proportion of human leukocyte markers was analyzed by flow cytometry.
Results
As a result of HSC hu-mice analysis, the transplantation efficacy was enhanced that hCD45 of STKO exceeded 50% at 8 weeks after HSC transplantation, which was more than 50% greater than that of SID. The engraftment of hCD45 and hCD3 in STKO was significantly improved compared to SID until the last measurement and GvHD symptoms were also reduced in STKO. Similarly, the PBMC hu-mice studies showed that human leukocyte transplantation efficacy and GvHD symptoms were improved in STKO. Especially, in the study applying low-dose PBMC to young mice, long-term studies were possible with minimal clinical signs despite the significant human leukocyte engraftment.
Conclusions
In the HSC hu-mice and the PBMC hu-mice analyses, the transplantation and the differentiation of immune cells were significant, and GvHD symptoms were alleviated in STKO mice. To relieve GvHD symptoms, we applied low-dose PBMC to 4 week old mice and observed minimal health problems in STKO with improved human immune cell reconstitution. In conclusion, STKO mice is expected to be a novel and useful platform for various immune studies, considering enhanced transplantation efficiency with the stable health of the animal.
Legal entity responsible for the study
The animal study was approved and monitored by the Institutional Animal Care and Use Committee of Asan Institute for Life Sciences (Seoul, Korea, IACUC No. 2022-12-123).
Funding
National Research Foundation of Korea grant (NRF-2020R1C1C1014653).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
124P - AI-designed cancer vaccines: Antigens from the dark genome are promising cancer vaccine targets
Presenter: Daniela Kleine-Kohlbrecher
Session: Poster Display session
125P - Enhancing the efficacy of neoantigen tumor vaccines in melanoma treatment through different administration times
Presenter: Kai Xiao
Session: Poster Display session
126P - Combination of oncolytic viruses, radiation therapy, and immune checkpoint inhibitor treatment in a breast cancer model
Presenter: Olga Bezborodova
Session: Poster Display session
127P - Combining chemotherapy and checkpoint inhibitors with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine to treat pancreatic ductal adenocarcinoma
Presenter: Nea Ojala
Session: Poster Display session
128P - Non-coding DNA lipid nanoparticles elicit antitumor immune responses and synergize with anti-PDL1 antibodies in mouse models of hepatocellular carcinoma
Presenter: Alba Rodriguez Garcia
Session: Poster Display session
129P - Computational approaches for enhancing the efficacy of cancer immunotherapy
Presenter: Byungho Lim
Session: Poster Display session
130P - Neoadjuvant treatment with a bispecific antibody cadonilimab in dMMR/MSI-H locally advanced colorectal cancer: Preliminary results from a phase II trial
Presenter: Caifeng Gong
Session: Poster Display session
131P - The efficacy and safety of cadonilimab with or without trastuzumab in combination with SOX as first-line (1L) treatment for advanced gastric (G) or gastroesophageal Junction adenocarcinoma (GEJA)
Presenter: Wenhui Yang
Session: Poster Display session
132P - An open-label, prospective phase II study of cadonilimab in combination with neoadjuvant chemotherapy for patients diagnosed with advanced ovarian cancer (AK104-IIT-003)
Presenter: Jie Tang
Session: Poster Display session